Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths
Esther González-López(Children's Cancer and Leukaemia Group), Pablo García‐Pavía(Universidad Francisco de Vitoria), Agnese Milandri(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Serena Foffi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Fernándo Domínguez(Hospital Universitario Puerta de Hierro Majadahonda), Clara Salas(Hospital Universitario Puerta de Hierro Majadahonda), Christian Gagliardi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), F. Javier de Haro-del Moral(Hospital Universitario Puerta de Hierro Majadahonda), Enrique Lara‐Pezzi(Spanish National Centre for Cardiovascular Research), Candida Cristina Quarta(Boston University), Massimiliano Lorenzini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Luis Alonso‐Pulpón(Hospital Universitario Puerta de Hierro Majadahonda), Claudio Rapezzi(Boston University), Mario Cinelli(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Marta Cobo Marcos(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 373
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
|European Heart Journal|2015|1.1k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k